nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-169-9-50-55nogr-1230Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYУровень онкофетальных белков в патологических тканях больных раком желудкаLevels of oncofetal proteins in pathological tissues of patients with gastric cancerКитО. И.KitO. I.

Кит Олег Иванович, генеральный директор, заслуженный врач РФ, доктор мед. наук, профессор, член-корр. РАН, 344037, Ростов-на-Дону, Россия

Kit Oleg Ivanovich, General Director, Honored Doctor of the Russian Federation, D. Med. Sc., Professor, CorrespondingMember of RAS, 344037, Rostov-on-Don, Russia

ФранциянцЕ. М.FrantsiyantsE. M.

Франциянц Елена Михайловна, руководитель лаборатории изучения патогенеза злокачественных опухолей, д. б. н., профессор, 344037, Ростов-на-Дону, Россия

Frantsiyants Elena Mikhaylovna, Head of Laboratory of Malignant Tumor Pathogenesis Study, D. Biol. Sc., Professor, 344037, Rostov-on-Don, Russia

КаплиеваИ. В.KaplievaI. V.

Каплиева Ирина Викторовна, с. н. с. лаборатории изучения патогенеза злокачественных опухолей, д. м. н., 344037, Ростов-на-Дону, Россия

Kaplieva Irina Viktorovna, Senior researcher of Laboratory of Malignant Tumor Pathogenesis Study, D. Med. Sc., 344037, Rostov-on-Don, Russia

kaplirina@yandex.ruГеворкянЮ. А.GevorkyanYu. A.

Геворкян Юрий Артушевич, руководитель отделения абдоминальной онкологии № 2, д. м. н., профессор, 344037, Ростов-на-Дону, Россия

Gevorkyan Yuryi Artushevich, Head of Department of Abdominal Oncology No.2, D. Med. Sc., Professor, 344037, Rostov-on-Don, Russia

СолдаткинаН. В.SoldatkinaN. V.

Солдаткина Наталья Васильевна, с. н. с. отделения абдоминальной онкологии № 2, д. м. н., 344037, Ростов-на-Дону, Россия

Soldatkina Natalia Vasilevna, Senior researcher of Department of Abdominal Oncology No.2., D. Med. Sc., 344037, Rostov-on-Don, Russia

ДженковаН. В.DzhenkovaE. A.

Дженкова Елена Алексеевна, учёный секретарь, д. б. н., доцент, 344037, Ростов-на-Дону, Россия

Dzhenkova Elena Alekseevna, Scientifi c Secretary, D. Biol.Sc., Assistant Professor, 344037, Rostov-on-Don, Russia

СамойленкоН. С.SamoylenkoN. S.

Самойленко Николай Сергеевич, аспирант отделения абдоминальной онкологии № 2, 344037, Ростов-на-Дону, Россия

Samoylenko Nikolay Sergeevich, Postgraduate student of Department of Abdominal Oncology No.2., 344037, Rostov-on-Don, Russia

ПогореловаЮ. А.PogorelovaYu. A.

Погорелова Юлия Александровна, с. н. с. лаборатории изучения патогенеза злокачественных опухолей, к. б. н., 344037, Ростов-на-Дону, Россия

Pogorelova Yulia Aleksandrovna, Senior researcher of Laboratory of Malignant Tumor Pathogenesis Study, Cand. Biol. Sc., 344037, Rostov-on-Don, Russia

Федеральное государственное бюджетное учреждение «Ростовский научно-исследовательский институт» Минздрава Российской ФедерацииРоссияRostov Research Institute of OncologyRussian Federation201920092019095055Copyright © Кит О.И., Франциянц Е.М., Каплиева И.В., Геворкян Ю.А., Солдаткина Н.В., Дженкова Н.В., Самойленко Н.С., Погорелова Ю.А., 20202020Кит О.И., Франциянц Е.М., Каплиева И.В., Геворкян Ю.А., Солдаткина Н.В., Дженкова Н.В., Самойленко Н.С., Погорелова Ю.А.Kit O.I., Frantsiyants E.M., Kaplieva I.V., Gevorkyan Y.A., Soldatkina N.V., Dzhenkova E.A., Samoylenko N.S., Pogorelova Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1230Цель исследования

Цель исследования. Изучение содержания СА-19.9, СА-125, СА-72.4 и Не-4 в ткани злокачественной опухоли, брюшины и сальника у больных раком желудка T3–4аN0–3M1 и T3–4аN0–3M0.

Материалы и методы

Материалы и методы. В исследование включено 62 пациента: 21 (10♂, 11♀) — с диагнозом рак желудка T3–4аN0–3M1 и метастатическим поражением брюшины; 24 (15♂, 9♀)– с диагнозом рак желудка T3–4аN0–3M0 без метастатического поражения; 17 (6♂, 11♀) — с неонкологической патологией — контроль. В ткани брюшины, большого сальника и рака желудка (РЖ) ИФА методами определяли уровни онкофетальных белков.

Результаты

Результаты. Установлено, что в ткани РЖ, сальника и брюшины увеличивалось содержание практически всех исследуемых факторов. У пациентов с распространённым процессом количество Не-4 и СА-19,9 во всех тканях возрастало в большей степени, чем у основной части пациентов без метастазов: в ткани РЖ –соответственно в 2,6 раза и в 1,8 раза (р<0,05), в сальнике — соответственно в 24,4 раза и в 4,8 раза, в брюшине — соответственно в 2,1 раза и в 8,5 раза. В сальнике у пациентов с распространённым процессом в большей степени также увеличивались концентрации СА-72.4 — в 6,1 раза и СА-125 — в 2,1 раза. У меньшей части пациентов с диагнозом рак желудка T3–4аN0–3M0, у которых уровень СА-19,9 в сальнике и брюшине был таким же высоким, как и у пациентов с T3–4аN0–3M1, через 4–6 месяцев после исследования развивались метастазы в соответствующих тканях.

Заключение

Заключение. Насыщенность ткани брюшины и сальника маркерными онкобелками является одним из факторов, связанных с особенностями метастазирования рака желудка, при этом уровень СА-19.9 может служить информативным лабораторным тестом для предикторной оценки характера дальнейшего развития заболевания.

Aim

Aim. Study of levels of CA-19.9, CA-125, CA-72.4 and He-4 in tissues of tumor, peritoneum and omentum in patients with gastric cancer T3–4аN0–3M1 and T3–4аN0–3M0.

Materials and methods

Materials and methods. The study included 62 patients: 21 (10♂, 11♀) — gastric cancer T3–4аN0–3M1 and peritoneal metastases; 24 (15♂, 9♀) — gastric cancer T3–4аN0–3M0 without metastases; 17 (6♂, 11♀) — non-cancer patients (controls). Levels of oncofetal proteins were measured by ELISA in tissues of the peritoneum, greater omentum, and gastric tumors (GT).

Results

Results. Levels of practically all studied factors were elevated in tissues of GT, omentum and peritoneum. Levels of He-4 and CA-19.9 in all tissues of patients with advanced cancer increased higher than in the majority of patients without metastases: in GT — respectively by 2.6 and 1.8 times (p<0.05), in the omentum — respectively by 24.4 and 4.8 times, in the peritoneum — respectively by 2.1 and 8.5 times. Omental tissues of patients with advanced cancer showed a higher increase in levels of CA-72.4 and CA-125 as well — by 6.1 and 2.1 times, respectively. A small number of patients with T3–4аN0–3M0 gastric cancer, who had CA-19.9 in the omentum and peritoneum as high as in patients with T3–4аN0–3M1, developed metastases in the corresponding tissues 4–6 months after the study.

Conclusion

Conclusion. The content of oncoprotein markers in tissues of the peritoneum and omentum is one of the factors associated with metastatic characteristics, and CA-19.9 level can serve as an informative laboratory test for the predictive assessment of the further disease development.

рак желудкаметастатические нишионкофетальные белкиgastric cancermetastatic nichesoncofetal proteinsReferencesКит О. И. Нейроэндокринные, клинические и молекулярно-биологические аспекты рака желудка. – Рост./Д.: ЗАО «Ростиздат», 2012.Kit O. I. Nejroendokrinnye, klinicheskie i molekulyarno-biologicheskie aspekty raka zheludka [Neuroendocrine, clinical and molecular biological aspects of gastric cancer]. Rostov-on-Don, ZAO “Rostizdat”, 2012.Mikuła-Pietrasik J., Uruski P., Tykarski A., Książek K. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cellular and Molecular Life Sciences, 2018, vol.75, no. 3, pp.509–525. http://doi.org/10.1007/s00018–017–2663–1.Mikuła-Pietrasik J., Uruski P., Tykarski A., Książek K. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cellular and Molecular Life Sciences, 2018, vol.75, no. 3, pp.509–525. http://doi.org/10.1007/s00018–017–2663–1.Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, no.1, pp.571–573. doi: 10.1016/S0140–6736(00)49915–0.Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, no.1, pp.571–573. doi: 10.1016/S0140–6736(00)49915–0.Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell. Biol., 2006, no.8, pp. 1369–1375. doi: 10.1038/ncb1507.Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell. Biol., 2006, no.8, pp. 1369–1375. doi: 10.1038/ncb1507.Tsai J.H., Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev., 2013, no.27, pp.2192–2206. doi: 10.1101/gad.225334.113.Tsai J.H., Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev., 2013, no.27, pp.2192–2206. doi: 10.1101/gad.225334.113.Kaplan RN, Rafi i S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006;66:11089–11093. doi: 10.1158/0008–5472.CAN-06–2407.Kaplan RN, Rafi i S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006;66:11089–11093. doi: 10.1158/0008–5472.CAN-06–2407.Shimada H., Noie T., Ohashi M. et al. Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, no.17, pp.26–33. doi: 10.1007/s10120–013–0259–5.Shimada H., Noie T., Ohashi M. et al. Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, no.17, pp.26–33. doi: 10.1007/s10120–013–0259–5.Kim J.H., Jun K. H., Jung H. et al. Prognostic value of preoperative serum levels of five tumor markers (Carcinoembryonic Antigen, CA19–9, Alphafetoprotein, CA72–4, and CA125) in gastric cancer. Hepatogastroenterology, 2014, no.61, pp.863–869.Kim J.H., Jun K. H., Jung H. et al. Prognostic value of preoperative serum levels of five tumor markers (Carcinoembryonic Antigen, CA19–9, Alphafetoprotein, CA72–4, and CA125) in gastric cancer. Hepatogastroenterology, 2014, no.61, pp.863–869.Yu J., Zhang S., Zhao B. Differences and correlation of serum CEA, CA19–9 and CA72–4 in gastric cancer. Mol. Clin. Oncol., 2016, no.4, pp.441–449. doi: 10.3892/mco.2015.712.Yu J., Zhang S., Zhao B. Differences and correlation of serum CEA, CA19–9 and CA72–4 in gastric cancer. Mol. Clin. Oncol., 2016, no.4, pp.441–449. doi: 10.3892/mco.2015.712.Zhou H., Dong A., Xia H. et al. Associations between CA19–9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer. Oncologyletters, 2018, vol. 16, no. 1, pp. 1079–1086.Zhou H., Dong A., Xia H. et al. Associations between CA19–9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer. Oncologyletters, 2018, vol. 16, no. 1, pp. 1079–1086.Kim D.H., Yun H. Y., Ryu D. H. et al. Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World journal of gastroenterology, 2015, vol. 21, no. 4, pp. 1216–1221.Kim D.H., Yun H. Y., Ryu D. H. et al. Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients. World journal of gastroenterology, 2015, vol. 21, no. 4, pp. 1216–1221.Kim D.H., Kim S. M., Hyun J. K. et al. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods. Ann. Surg. Oncol., 2013, no.20, pp. 2317–2327.Kim D.H., Kim S. M., Hyun J. K. et al. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods. Ann. Surg. Oncol., 2013, no.20, pp. 2317–2327.Bingle L., Singleton V., Bingle C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, no. 21, pp. 2768–73.10.1038/sj.onc.1205363Bingle L., Singleton V., Bingle C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, no. 21, pp. 2768–73.10.1038/sj.onc.1205363James N.E., Chichester C., Ribeiro J. R. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. Frontiers in oncology, 2018, no. 8, p. 124. doi: 10.3389/fonc.2018.00124James N.E., Chichester C., Ribeiro J. R. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. Frontiers in oncology, 2018, no. 8, p. 124. doi: 10.3389/fonc.2018.00124Moore R.G., McMeekin D.S., Brown A. K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol., 2009, no.112, pp.40–6.10.1016/j.ygyno.2008.08.031.Moore R.G., McMeekin D.S., Brown A. K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol., 2009, no.112, pp.40–6.10.1016/j.ygyno.2008.08.031.Bingle L., Cross S. S., High A. S. et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res, 2006, no.7, p. 61.10.1186/1465–9921–7–61Bingle L., Cross S. S., High A. S. et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res, 2006, no.7, p. 61.10.1186/1465–9921–7–61LeBleu V.S., Teng Y., O’Connell J.T. et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nature medicine, 2013, no. 19, pp. 227–231.LeBleu V.S., Teng Y., O’Connell J.T. et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nature medicine, 2013, no. 19, pp. 227–231.Nagy B. Jr., Krasznai Z. T., Balla H. et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Annals of clinical biochemistry, 2012, no. 49, pp. 377–380.Nagy B. Jr., Krasznai Z. T., Balla H. et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Annals of clinical biochemistry, 2012, no. 49, pp. 377–380.Wan J., Wang Y., Cai G. et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget, 2016, vol.7, no.42, pp.67748–67759.Wan J., Wang Y., Cai G. et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget, 2016, vol.7, no.42, pp.67748–67759.Strimbu K., Tavel J. A. What are biomarkers? Current Opinion in HIV and AIDS, 2010, vol. 5, no. 6, pp. 463–466. doi: 10.1097/COH.0b013e32833ed177.Strimbu K., Tavel J. A. What are biomarkers? Current Opinion in HIV and AIDS, 2010, vol. 5, no. 6, pp. 463–466. doi: 10.1097/COH.0b013e32833ed177.Hanash S.M., Pitteri S. J., Faca V. M. Mining the plasma proteome for cancer biomarkers. Nature, 2008, vol. 452, no. 7187, pp. 571–579.Hanash S.M., Pitteri S. J., Faca V. M. Mining the plasma proteome for cancer biomarkers. Nature, 2008, vol. 452, no. 7187, pp. 571–579.Ludwig J.A., Weinstein J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer, 2005, vol. 5, no. 11, pp. 845–856.Ludwig J.A., Weinstein J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer, 2005, vol. 5, no. 11, pp. 845–856.Yotsukura S., Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Critical Reviews in Oncology/Hematology, 2014, vol. 93, no. 2, pp. 103–115.Yotsukura S., Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Critical Reviews in Oncology/Hematology, 2014, vol. 93, no. 2, pp. 103–115.Kirwan A., Utratna M., O’Dwyer M.E. et al. Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. BioMed research international, 2015, 490531.Kirwan A., Utratna M., O’Dwyer M.E. et al. Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. BioMed research international, 2015, 490531.Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol., 2010, no. 177, pp. 1053–1064. doi: 10.2353/ajpath.2010.100105.Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol., 2010, no. 177, pp. 1053–1064. doi: 10.2353/ajpath.2010.100105.Coccolini F., Gheza F., Lotti M. et al. Peritoneal carcinomatosis. World Journal of Gastroenterology: WJG, 2013, vol. 19, no. 41, pp. 6979–6994. http://doi.org/10.3748/wjg.v19.i41.6979Coccolini F., Gheza F., Lotti M. et al. Peritoneal carcinomatosis. World Journal of Gastroenterology: WJG, 2013, vol. 19, no. 41, pp. 6979–6994. http://doi.org/10.3748/wjg.v19.i41.6979Low R.N. MR imaging of the peritoneal spread of malignancy. Abdom. Imaging., 2007, no. 32, pp. 267–283. doi: 10.1007/s00261–007–9210–8.Low R.N. MR imaging of the peritoneal spread of malignancy. Abdom. Imaging., 2007, no. 32, pp. 267–283. doi: 10.1007/s00261–007–9210–8.Nowicka A., Marini F. C., Solley T. N. et al. Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance. PLoS ONE, 2013, vol. 8, no. 12, e81859.http://doi.org/10.1371/journal.pone.0081859.Nowicka A., Marini F. C., Solley T. N. et al. Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance. PLoS ONE, 2013, vol. 8, no. 12, e81859.http://doi.org/10.1371/journal.pone.0081859.Gerber S.A., Rybalko V. Y., Bigelow C. E. et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am. J. Pathol., 2006, no. 169, pp. 1739–1752. doi: 10.2353/ajpath.2006.051222.Gerber S.A., Rybalko V. Y., Bigelow C. E. et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am. J. Pathol., 2006, no. 169, pp. 1739–1752. doi: 10.2353/ajpath.2006.051222.Lambert A.W., Pattabiraman D. R., Weinberg R. A. Emerging Biological Principles of Metastasis. Cell, 2017, vol. 168, no. 4, pp. 670–691.Lambert A.W., Pattabiraman D. R., Weinberg R. A. Emerging Biological Principles of Metastasis. Cell, 2017, vol. 168, no. 4, pp. 670–691.

The authors declare that there are no conflicts of interest present.